Close

How FAP Partnerships Enhance Pharma Supply Chain Resilience

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...

State of API & Peptide CDMO Capacity

Pharmaceutical companies planning peptide or complex small-molecule launches are...

What Goes Into Synthetic Urine? The Chemistry Behind Replicating a Biological Fluid

Synthetic urine sounds simple until you look closely at...
- Advertisement -

The pharmaceutical industry stands as an economic juggernaut, boasting a global valuation estimated at approximately $1.27 trillion in 2021. This remarkable figure underscores the industry’s indispensable role in healthcare, delivering life-saving medications, vaccines, and treatments to individuals worldwide. Beyond its impact on public health, the pharmaceutical sector is a driving force behind economic growth and innovation. It spearheads research and development, generates employment opportunities, and enhances overall societal well-being.

Behind the scenes, the pharmaceutical supply chain is an intricate web of interconnected processes overseeing the secure and punctual delivery of medications from manufacturers to patients. This complex network involves numerous stakeholders, including drug manufacturers, wholesalers, distributors, pharmacies, healthcare providers, and patients.

These stakeholders face a multitude of challenges, encompassing the assurance of temperature-controlled medication efficacy and the handling of specialized medications and live agents. Additionally, pharmaceutical companies must navigate unique regulatory requirements, given their status as a critical product category that our nation must safeguard. A deeper exploration of the various hurdles encountered by this industry underscores the necessity of robust data for cost reduction and operational streamlining.

Addressing Supply Chain Challenges: The Role of a Freight Audit and Payment (FAP) Partner

Liability Management

Effectively managing liability when shipping high-value medications is of paramount importance in the pharmaceutical supply chain. Due to the substantial value and sensitivity of these products, shippers often exhaust their liability insurance coverage to safeguard against potential losses or damages. In some cases, relying solely on insurance may prove insufficient in addressing all liability concerns.

A proficient Freight Audit and Payment (FAP) partner can offer invaluable assistance in liability management for shipping high-value medications. They can verify that carriers and logistics service providers meet the requisite quality standards and possess the necessary certifications for handling pharmaceutical products. This reduces the probability of errors or mishandling during transportation, thereby minimizing the risk of damage or loss. A FAP partner can also provide insights for selecting carriers based on their track record, reputation, and experience in handling high-value pharmaceutical shipments.

Transit Precision

Maintaining precise temperature control is of utmost significance in the pharmaceutical supply chain. Numerous medications are highly sensitive to temperature fluctuations, making it essential to preserve their potency and safety.

Another challenge lies in the transportation of specialized medications and live agents, including organ transplants, gene therapies, and personalized medicines, which require specific storage and transportation conditions. Ensuring their timely delivery presents a formidable task.

These intricacies within the pharmaceutical supply chain underscore the significance of data and the demand for efficient FAP solutions. Given the vast volume of medications transported globally, accurate allocation, auditing, and payment processes are indispensable for maintaining a well-functioning supply chain.

Traceable Data

Traceable data, offering end-to-end visibility, assumes critical importance in the pharmaceutical supply chain, especially concerning unit-level serialized product data for each shipment. The ability to track and trace individual items throughout the supply chain yields valuable insights and ensures accountability for product movement and handling. A reputable FAP partner plays a pivotal role in facilitating this traceability process, which becomes mandatory after the Drug Supply Chain Security Act’s (DSCSA) November 27 deadline for implementing requirements to enhance patient safety.

Advanced data management systems and technologies can assist in capturing and analyzing unit-level serialized product data for each shipment. This enables comprehensive end-to-end visibility, enabling companies to monitor the journey of their products from manufacturing to end-user delivery. This granular level of traceability aids in identifying potential complications, such as product recalls or disruptions, empowering manufacturers to take swift corrective actions.

Network Optimization

Network optimization assumes a crucial role in ensuring the availability and accessibility of essential medications as part of national security measures. By strategically designing and managing the pharmaceutical supply chain network, it becomes feasible to efficiently distribute medications to healthcare facilities and pharmacies, even during high-demand or emergency scenarios like the COVID-19 pandemic. Finding the right partner can provide valuable assistance in network optimization, contributing to the consistent availability of essential medications.

FAP partners leverage data analytics and modeling techniques to assess and optimize factors such as demand patterns, geographic coverage, transportation routes, and inventory levels. These improvements may involve streamlining distribution center operations, enhancing transportation routes, or adjusting inventory stock levels.

Discovering the Ideal Freight Audit and Payment Technology

Data-driven approaches have revolutionized the management of carriers and logistics service providers within the pharmaceutical supply chain. Timely and accurate delivery is of paramount importance in this industry.

Manufacturers can gain real-time visibility into shipment status, monitor temperature conditions, and track product locations, all thanks to robust data. This enables proactive intervention in the event of deviations from desired conditions.

One example of technology facilitating data-driven supply chain management is Radio Frequency Identification (RFID) tags. When affixed to individual product units or shipping containers, these small electronic devices allow for the collection and transmission of data, including location, temperature, and humidity. This data can be accessed and analyzed in real time, providing valuable insights into product conditions during transit.

Pharmaceutical companies recognize that shipping decisions cannot solely hinge on cost considerations. Utilizing a reliable and efficient FAP partner can significantly aid in managing the intricacies of the pharmaceutical supply chain. By offering comprehensive workflows and financial integration, a dependable FAP partner promotes seamless collaboration between shippers and carriers, ensuring timely carrier payments and fostering stronger shipper-carrier relationships.

Ultimately, the effective utilization of data in the pharmaceutical supply chain enhances service quality, reduces risks, and bolsters resilience. Real-time data monitoring and analysis facilitate proactive intervention, resulting in improved product quality, transit times, and overall supply chain performance. As the industry continues to evolve, the judicious use of data will remain a pivotal element in navigating the complexities of the pharmaceutical supply chain.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...

State of API & Peptide CDMO Capacity

Pharmaceutical companies planning peptide or complex small-molecule launches are...

What Goes Into Synthetic Urine? The Chemistry Behind Replicating a Biological Fluid

Synthetic urine sounds simple until you look closely at...

Danaher Prepares to Introduce Advanced AI-Powered Laboratory

In a significant step for pharmaceutical research, Danaher has...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »